Cancer Biology & Medicine

►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".


►►Very important notification on publication fee

Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.

Cancer Biology & Medicine

Cancer Biology & Medicine is a peer-reviewed open-access journal published by the China Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:

● Cancer genetics

● Cancer and stem cell biology

● Molecular and clinical immunology

● Cancer prevention and epidemiology

● Cancer biomarkers

● Radiation oncology

● Oncology clinical trials

● Mechanisms of drug sensitivity and resistance

● Targeted therapy and immunotherapy

● Multidisciplinary treatment and personalized medicine

Author Benefits

● Easy submission via online system

● Efficient and professional peer review

● Rapid pre-print online publication

● No charge for publication and open access

● International visibility-All full texts are free in PubMed Central




Publication of the 2nd issue in 2021


In this issue, contents of five reviews focus on application of nano-medicine in cancer theranostics, which refer to stimuli-responsive nanocarriers, nanotechnology-based theranostic systems, delivery vehicles related to vaccine development, Gold-based nanomaterials in brain cancer treatment, and nanotechnology in overcoming drug resistance. Meanwhile, circular RNA, as another important topic, is involved in reviews on its role in epithelial-mesenchymal transition and chemoresistance as well as its potential clinical values.

Original researches also include some new discoveries on basic and clinical researches. For instance, results from the following 2 papers are full of novelty and practical value: “rBRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees” and “The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma”. Except for the aforementioned contents, other summaries and researches are also highly recommended. We hope the issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine.

Posted: 2021-05-14

Publication of the 1st issue in 2021


Basic research on oncology is the main content of this issue. Epigenetics and updated immunotherapy targets for lymphoma, the roles of some molecules in development of lung cancer, as well as other contents including tumor microenvironment, DNA damage, response for cancer therapy and so on are included.

A review discussing intermittent fasting induces an interesting topic. Another systematic review focuses cancer patients with COVID-19.Original clinical studies are also worthy of reading indeed, including biomarkers for diagnosis of hepatocellular carcinoma, relevant of systemic inflammation and BMI with survivals of upper digestive duct cancers, comparison of different treatment for bladder cancer etc. We hope the issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine.

Posted: 2021-02-05
More Announcements...

Vol 18 (2021): Online first articles

Table of Contents


The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma PDF
Xianxian Wu, et al. 1-10
Epithelial-mesenchymal transition-related circular RNAs in lung carcinoma PDF
Meina Jiang, et al. 1-10
Biological roles and potential clinical values of circular RNAs in gastrointestinal malignancies PDF
Xueping Tao, et al. 1-21
Biomaterial-based platforms for cancer stem cell enrichment and study PDF
Chunhua Luo, et al. 1-12
Stimuli-responsive nanocarriers for therapeutic applications in cancer PDF
Xubo Zhao, et al. 1-17
Circular RNAs: new biomarkers of chemoresistance in cancer PDF
Jiaqi Wang, et al. 1-16
Nanotechnology assisted photo- and sonodynamic therapy for overcoming drug resistance PDF
Rui Li, et al. 1-13
Recent progress of nanotechnology-based theranostic systems in cancer treatments PDF
Ying Xue, et al. 1-16

Original Article

LncRNA HIF1A-AS2 accelerates malignant phenotypes of renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA PDF
Mingwei Chen, et al. 1-18
NEDD9 promotes cancer stemness by recruiting myeloidderived suppressor cells via CXCL8 in esophageal squamous cell carcinoma PDF
Dongli Yue,et al. 1-18
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees PDF
Laura Cortesi, et al. 1-7
Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids PDF
Lisi Zeng, et al. 1-31
A nomogram-based immune-serum scoring system predicts overall survival in patients with lung adenocarcinoma PDF
Qiujuan Huang, et al. 1-15
Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer PDF
Nanlin Hu, et al. 1-11
Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies PDF
Winnie Yeo, et al. 1-8
Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases PDF
Zhen Zhou, et al 1-12
L1CAM overexpression promotes tumor progression through recruitment of regulatory T cells in esophageal carcinoma PDF
Xuan Zhao, et al. 1-15
Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver PDF
Xiangdong Ye, et al. 1-17
CD13 inhibition augments DR4-induced tumor cell death in a p-ERK1/2-independent manner PDF
Jun Ni, et al. 1-18
Analysis of the HNF4A isoform-regulated transcriptome identifies CCL15 as a downstream target in gastric carcinogenesis PDF
Zhen Ni, et al. 1-17
Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma PDF
Meiting Chen, et al. 1-8
SNORA23 inhibits HCC tumorigenesis by impairing the 2ʹ-O-ribose methylation level of 28S rRNA PDF
Zhiyong Liu, et al. 1-16
FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma PDF
Tao Chen, et al. 1-10
Overexpressed NEDD8 as a potential therapeutic target in esophageal squamous cell carcinoma PDF
Jingrong Xian, et al. 1-14
Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion PDF
Xin Wang, et al. 1-15
The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study PDF
Wei Zhang, et al. 1-8
The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma PDF
Yan Song, et al. 1-7
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial PDF
Tianqing Chu, et al. 1-9
Heat shock protein 90 promotes RNA helicase DDX5 accumulation and exacerbates hepatocellular carcinoma by inhibiting autophagy PDF
Ting Zhang, et al. 1-12
Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas PDF
Giacomo Miserocchi, et al. 1-15
VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo PDF
Guangbo Kang, et al. 1-16
A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma PDF
Chengming Liu, et al. 1-16
Drug repurposing for cancer treatment through global propagation with a greedy algorithm in a multilayer network PDF
Xi Cheng, et al. 1-16
Protein convertase subtilisin/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway PDF
Mingyan He, et al. 1-14
sLex expression in invasive micropapillary breast carcinoma is associated with poor prognosis and can be combined with MUC1/EMA as a supplementary diagnostic indicator PDF
Yawen Song, et al. 1-13
The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms PDF
Huihui Yin, et al. 1-13
Epstein-Barr virus DNA loads in the peripheral blood cells predict the survival of locoregionally-advanced nasopharyngeal carcinoma patients PDF
Yongqiao He, et al. 1-12
Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types PDF
Zhe Gong, et al. 1-12
Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma PDF
Fengjuan Jiang, et al. 1-13
CUL4B facilitates HBV replication by promoting HBx stabilization PDF
Haixia Shan, et al. 1-12